Patents Assigned to Asuragen, Inc.
-
Patent number: 12139755Abstract: The invention relates to methods of RNA amplification, including methods for the reverse transcription of cDNA from RNA using a thermostable reverse transcriptase. In a particular aspect, the methods are capable of linear amplification of an RNA template through multiple cycles of cDNA synthesis.Type: GrantFiled: December 20, 2021Date of Patent: November 12, 2024Assignee: ASURAGEN, INC.Inventors: Gary J. Latham, Richard Andrew Blidner, Liangjing Chen
-
Patent number: 11913068Abstract: Disclosed herein are data processing and calculating annotation systems and devices, and corresponding methods, for nucleic acid analysis. In particular, disclosed herein are methods for sizing a repeat region of a nucleic acid sample. For example, the methods disclosed herein use a ladder of amplification products to determine nucleic acid size.Type: GrantFiled: August 23, 2019Date of Patent: February 27, 2024Assignee: Asuragen, Inc.Inventors: Eran Bram, Raghav Shroff, Andrew Hadd, Blake Printy
-
Patent number: 11236384Abstract: The invention relates to methods of RNA amplification, including methods for the reverse transcription of cDNA from RNA using a thermostable reverse transcriptase. In a particular aspect, the methods are capable of linear amplification of an RNA template through multiple cycles of cDNA synthesis.Type: GrantFiled: January 16, 2018Date of Patent: February 1, 2022Assignee: ASURAGEN, INC.Inventors: Gary J. Latham, Richard Andrew Blidner, Liangjing Chen
-
Patent number: 11214829Abstract: Described herein are methods, compositions, kits, and uses thereof for analysis of nucleic acid segments comprising a repeating A/T-rich segment, wherein the repeating A/T-rich segment is: (i) a homopolymeric segment comprising at least 10 A residues, at least 10 T residues, or at least 10 U residues, wherein the at least 10 A, T, or U residues are consecutive or interrupted once by one to three other nucleotides; or (ii) a segment comprising (TnA)m, (ATn)m, (TAn)m, or (AnT)m, wherein n is 2 or greater and m is such that the length of the repeating A/T-rich segment is 10 or more residues.Type: GrantFiled: July 22, 2016Date of Patent: January 4, 2022Assignee: ASURAGEN, INC.Inventors: Gary J. Latham, Sachin Sah
-
Publication number: 20210189384Abstract: The present disclosure relates to methods and compositions for nucleic acid library preparation. In certain aspects, the present disclosure relates to methods of making a library of concatenated amplicons from a target nucleic acid. The present disclosure further relates to methods of using the methods and compositions described herein, e.g., in downstream applications such as sequencing (e.g., single-molecule sequencing), gene assembly, and/or structural variation characterization.Type: ApplicationFiled: November 25, 2020Publication date: June 24, 2021Applicant: Asuragen, Inc.Inventors: Gary J. LATHAM, Liangjing Chen
-
Publication number: 20200048696Abstract: Disclosed herein are data processing and calculating annotation systems and devices, and corresponding methods, for nucleic acid analysis. In particular, disclosed herein are methods for sizing a repeat region of a nucleic acid sample. For example, the methods disclosed herein use a ladder of amplification products to determine nucleic acid size.Type: ApplicationFiled: August 23, 2019Publication date: February 13, 2020Applicant: Asuragen, Inc.Inventors: Eran Bram, Raghav Shroff, Andrew Hadd, Blake Printy
-
Patent number: 10047388Abstract: The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.Type: GrantFiled: October 24, 2013Date of Patent: August 14, 2018Assignee: Asuragen, Inc.Inventors: David Brown, Rick Conrad, Eric Devroe, Marianna Goldrick, Kerri Keiger, Emmanuel Labourier, Ivonne Moon, Patricia Powers, Jeffrey Shelton, Jaclyn Shingara
-
Patent number: 9783848Abstract: This disclosure relates to methods of determining the presence and position of AGG or interruptor elements within a trinucleotide (for example, CGG) repeat region, and to methods of determining the number of repeats present in this region, by amplifying a set of products with a set of primers of which at least one comprises a portion of the CGG repeat region, and resolving the products to produce a representation of product size and abundance.Type: GrantFiled: February 26, 2014Date of Patent: October 10, 2017Assignee: Asuragen, Inc.Inventors: Gary J. Latham, Liangjing Chen, Sachin Sah
-
Patent number: 9777330Abstract: Methods are provided for determining the methylation status of GC-rich templates. The methods include use of GC reference standards that allow simultaneous characterization of methylation status and CGG repeat length. The methods are useful for detecting genotypes associated with GC-rich repeats, including Fragile X Syndrome.Type: GrantFiled: October 28, 2011Date of Patent: October 3, 2017Assignee: Asuragen, Inc.Inventors: Gary J. Latham, Liangjing Chen, Andrew Hadd, Sachin Sah, Ru Cao
-
Publication number: 20170121763Abstract: Disclosed herein are data processing and calculating annotation systems and devices, and corresponding methods, for nucleic acid analysis. In particular, disclosed herein are methods for sizing a repeat region of a nucleic acid sample. For example, the methods disclosed herein use a ladder of amplification products to determine nucleic acid size.Type: ApplicationFiled: November 3, 2016Publication date: May 4, 2017Applicant: Asuragen, Inc.Inventors: Eran Bram, Raghav Shroff, Andrew Hadd, Blake Printy
-
Patent number: 9540645Abstract: The present invention concerns methods and compositions for diagnosing and/or treating vascular diseases including cancer, cardiac diseases, vascular diseases of the eye, and inflammatory diseases. The methods involve measuring the levels of one or multiple miRNAs in patient samples and using the test results to diagnose and/or predict an optimal treatment regimen for the patient. Compositions described in the invention include nucleic acids that function as miRNAs or miRNA inhibitors that can be introduced to a patient to reduce or increase vascularization as needed.Type: GrantFiled: April 19, 2016Date of Patent: January 10, 2017Assignees: The John Hopkins University, ASURAGEN, Inc.Inventors: Jikui Shen, Kevin Kelnar, Jeffrey Shelton, David Brown, Peter Campochiaro
-
Patent number: 9506061Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: GrantFiled: May 14, 2015Date of Patent: November 29, 2016Assignee: ASURAGEN, INC.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Patent number: 9447414Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: GrantFiled: June 16, 2015Date of Patent: September 20, 2016Assignee: ASURAGEN, INC.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Patent number: 9382537Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: GrantFiled: August 13, 2014Date of Patent: July 5, 2016Assignee: ASURAGEN, INC.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Patent number: 9371560Abstract: Disclosed herein are methods for the automated reconstruction of a genotype of a gene, fragment, or genomic region using exhaustive enumeration. The methods can be used to reconstruct the genotype of any GC-rich sequence, such as the CGG repeat region in the 5? UTR of FMR1 or the CCG repeat region in the 5? UTR of FMR2. Also disclosed is an apparatus for use in conducting automated genotype reconstruction, as well as methods of diagnosis and treatment using exhaustive enumeration methods to reconstruct and identify genotypes associated with a disease or disorder.Type: GrantFiled: July 19, 2013Date of Patent: June 21, 2016Assignee: Asuragen, Inc.Inventors: Ashish Choudhary, Gary Latham, Sachin Sah
-
Patent number: 9080215Abstract: The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as cervical disease, and using the profile in assessing the condition of a patient.Type: GrantFiled: January 7, 2013Date of Patent: July 14, 2015Assignee: Asuragen, Inc.Inventors: Sylvie Beaudenon-Huibregtse, Emmanuel Labourier, Laura Elizondo
-
Patent number: 9068219Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: GrantFiled: August 13, 2014Date of Patent: June 30, 2015Assignee: Asuragen, Inc.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Patent number: 9051571Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: GrantFiled: April 16, 2014Date of Patent: June 9, 2015Assignee: Asuragen, Inc.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Publication number: 20150004221Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: ApplicationFiled: August 13, 2014Publication date: January 1, 2015Applicant: ASURAGEN, INC.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Publication number: 20150005366Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: ApplicationFiled: August 13, 2014Publication date: January 1, 2015Applicant: ASURAGEN, INC.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar